The company has already raised $5 million. A filing from 2012 shows that Adaptive was seeking more than $5 million and ended up raising $2.65 million.
Founded in 2009, Adaptive focuses on profiling the immune system. Its flagship product is the immunoSEQ, which the company describes as a "suite of next generation immune sequencing assays that allow researchers to view and analyze the T and B cells of the adaptive immune system with unprecedented depth and specificity."
Though the company names the academic or research institutions that are using Adaptive's technology - such as Stanford School of Medicine, Dana-Farber Cancer Institute and Harvard University - the company's website doesn't identify the pharma companies that are using the "quantitative characterizations of the immune repertoire made available by immunoSEQ assays to ask and answer critical questions about disease diagnosis, progression, and treatment."
However, on June 27, Adaptive announced that it has signed an agreement with Biogen to study the immune repertoire and search for immunological biomarkers in hard-to-reat autoimmune diseases.
The company, which spun out of the Fred Hutchinson Cancer Research Center in Seattle, is led by Chad Robins, also a co-founder. Until early 2012, the company was known as Adaptive TCR.
-- By Arundhati Parmar, Senior Editor, MD+DI